Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
momelotinib + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination regimen of momelotinib, capecitabine, and oxaliplatin is under clinical investigation for the treatment of advanced cancers, specifically relapsed or refractory metastatic pancreatic ductal adenocarcinoma. **Momelotinib** is a small-molecule inhibitor of Janus kinases (JAK1 and JAK2) and activin receptor type 1 (ACVR1), which disrupts cancer cell proliferation and inflammatory signaling. **Capecitabine** is a prodrug of 5-fluorouracil (5-FU), an antimetabolite chemotherapy agent that inhibits DNA synthesis. **Oxaliplatin** is a platinum-based chemotherapy that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. This triple combination is designed to target tumor growth and survival through multiple complementary mechanisms, enhancing antitumor efficacy compared to individual agents or doublet chemotherapy[3].
- Other names
- momelotinib + capecitabine + oxaliplatin
02
Targets
Beyond the preview
Go deeper on momelotinib + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on momelotinib + capecitabine + oxaliplatin.